Driving profitable growth through Gross-to-Net in pharma

Published on March 7, 2024

/**/

Explore how Gross-to-Net (GtN) optimization can boost growth opportunities for pharma companies. Simon-Kucher’s GtN excellence programs help unlock both short and long-term performance with meaningful improvements to Return on Sales.

Strategic optimization of Gross-to-Net (GtN) investments can unlock growth for the pharmaceutical industry, yet commercial and pricing teams frequently overlook its impact in driving profitable growth. 

GtN optimization refers to the process of measuring and optimizing the difference between a product’s initial gross sales and its net revenue after sales deductions and adjustments. This process evaluates the actual economic impact of a pharma company’s offerings by taking all price deductions into account, including discounts, rebates, clawbacks, and free goods. 

At Simon-Kucher, our GtN excellence programs thoroughly assess every lever leading to net revenue deductions, unlocking…

GtN blog